Pfizer Beats Q4 Estimates but Post-COVID Revenue Decline Forces a $10 Billion Bet on the Obesity Drug Boom
Pfizer topped Q4 2025 estimates with adjusted EPS of $0.66 but faces a challenging 2026 as COVID product revenue declines by $1.5 billion, pushing the pharma giant to stake its future on a $10 billion obesity drug acquisition.